DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Meester-Loeys syndrome — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMeester-Loeys syndrome maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for meester-loeys syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Meester-Loeys syndrome is an X-linked syndromic form of thoracic aortic aneurysm and dissection caused by mutations in the BGN gene. One iPSC line (BBANTWi009-A) has been generated from a boy carrying a hemizygous BGN mutation (chrX:153502980-153530518del, GRCh38). The line was made from dermal fibroblasts using a Sendai virus reprogramming kit, showed a normal karyotype, expressed pluripotency markers, and could differentiate into all three germ layers while retaining the original mutation. This is a cell line resource, not a treatment study.
Earlier literature on Loeys-Dietz syndrome, which shares some phenotypic overlap but is genetically distinct, describes an autosomal dominant disorder caused by mutations in TGFBR1, TGFBR2, TGFB2, or SMAD3. One 2006 report notes that fetal aortic root dilation can be detected as early as 19 weeks of gestation and serves as an early marker of the aggressive cardiovascular course. A 2014 case report describes anaesthetic management for a laparotomy in a patient with Loeys-Dietz syndrome type I, which accounts for more than 75% of cases, but provides no drug data.
No drug treatment, clinical trial, or survival or response rate data appear in any of these abstracts. The only experimental resource is a single iPSC line from one patient. What is missing is any drug intervention tested in Meester-Loeys syndrome, any animal model data, any patient cohort with measured outcomes, and any funding for a clinical trial or even a preclinical drug screen using the available cell line.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Prenatal Diagnosis · 2006 · 44 citations
Fetal aortic root dilation: a prenatal feature of the Loeys-Dietz syndrome
AbstractLoeys-Dietz syndrome is a recently described autosomal dominant disorder with cardinal manifestations in cardiovascular, craniofacial and skeletal systems. Although the disease has some phenotypic overlap with Marfan syndrome, the disease, that is caused by mutations in the transforming growth factor beta-receptor 1 (TGFBR1) or transforming growth factor beta-receptor 2 (TGFBR2) genes, presents many distinctive features and a particularly aggressive cardiovascular course. We describe prenatal identification of an aortic root aneurysm in a fetus of 19 week of gestation as an early marker of Loeys-Dietz syndrome.
Journal of Evolution of Medical and Dental Sciences · 2014 · 0 citations · open access
ANAESTHETIC MANAGEMENT FOR A RARE CASE OF LOEYS - DIETZ SYNDROME FOR LAPAROTOMY
AbstractLoeys-Dietz syndrome (LDS) is an autosomally dominant connective tissue disorder characterised by vascular and skeletal manifestations. It is caused by mutations in the TGFBR1, TGFBR2, TGFB2 or SMAD3 genes. There are four types of which type I is the most common accounting for more than 75% of the cases. Here we report the anaesthetic management of a case of LDS type I who presented with abdominal pain with suspected twisted ovarian cyst for laparotomy.
Stem Cell Research · 2022 · 0 citations · open access
Generation of an induced pluripotent stem cell (iPSC) line (BBANTWi009-A) from a Meester-Loeys syndrome patient carrying a BGN mutation
AbstractMeester-Loeys syndrome (MRLS) is an X-linked syndromic form of thoracic aortic aneurysm and dissection. Here, we report an iPSC line (BBANTWi009-A) of a boy carrying a hemizygous BGN mutation (chrX:153502980-153530518del, GRCh38) causing MRLS. iPSCs were generated from dermal fibroblasts by reprogramming with the Cytotune®-iPS 2.0 Sendai Reprogramming Kit (Invitrogen). The generated iPSCs showed a normal karyotype, expressed pluripotency markers, were differentiated into the three germ layers and carried the original genotype.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
